Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 222

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 222
---
 named executive officers base salaries were as follows: $306,000 for Dr. Atay, $306,000 for Mr. Taylor, and $270,300 for Ms. Johnson. Effective from July 1, 2024, each of Dr. Atay and Mr. Taylor became eligible to be considered for a discretionary annual incentive bonus, subject to their continued employment through the date that bonuses are paid. Equity compensation Historically, the equity compensation granted to our named executive officers has consisted of stock options. For a description of the stock options granted to our named executive officers in fiscal year 2024, please see the “Outstanding equity awards at 2024 fiscal year-end”table below. 176

Employee benefits and perquisites Our named executive officers are eligible to participate in our health and welfare plans to the same extent as are full-time employees generally. We generally do not provide our named executive officers with perquisites or other personal benefits. Retirement benefits We have established a 401(k) tax-deferredsavings plan, which permits participants, including our named executive officers, to make contributions by salary deduction pursuant to Section 401(k) of the Internal Revenue Code. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees, including a 100% company matching contribution of the first 3% of an employee’s contribution, and then 50% of the next 2% of an employee’s contribution. Employment arrangements with named executive officers Our named executive officers have not previously entered into written employment agreements with us. We intend to enter into confirmatory employment letters with each of our named executive officers which will become effective upon the completion of this offering and will set forth the continuing terms of their employment. We intend that the written employment agreements with each of our named executive officers will cross-reference our Executive Severance and Change in Control Plan, pursuant to which they will each be eligible to receive certain severance and change in control benefits, as described in “Severance and Change in Control Benefits” below. Outstanding equity awards at 2024 fiscal year-end The following table sets forth information regarding each unexercised option held by each of our named executive officers as of December 31, 2024. The vesting schedule applicable to each outstanding award is described in the footnotes to the table below. Unless otherwise noted, all of the outstanding equity awards reported in the following table were granted under our 2018 Plan.

| Name              |     | Number of